Amgen’s $27.8 Billion Deal for Horizon Therapeutics Clears Key Hurdle

[ad_1] The Federal Trade Commission said it had agreed to end its legal challenge of the $27.8 billion deal. The pact also dismisses the antitrust claims of six states that…

Walgreens Chief Executive Rosalind Brewer Steps Down

[ad_1] Rosalind Brewer has stepped down less than three years after taking the helm of the pharmacy operator. [ad_2] Source link

FTC Pauses Challenge to Amgen’s $27.8 Billion Deal for Horizon Therapeutics

[ad_1] The move gives the agency time to weigh a settlement that would allow the deal to close with conditions. [ad_2] Source link

VinFast, Arm and Other Index Orphans Miss Out on Billions From Passive Investors

[ad_1] VinFast, the Vietnamese electric-vehicle maker, and Arm, a British chip designer, are caught in a weird limbo thanks to their decisions on where to list their shares. [ad_2] Source…

Opinion | Gilead Sciences Is the Target of a Bizarre Legal Theory

[ad_1] A lawsuit claims the biotech innovator should have rolled out a new drug sooner. [ad_2] Source link

Get In on This Skin Disease Drug Before Big Pharma Does

[ad_1] What to Read Next [ad_2] Source link

Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

[ad_1] Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workforce executed to align with focus on…

New Gene Therapy Could Face Uphill Battle Despite FDA Approval

[ad_1] The FDA approval of BioMarin’s gene therapy for hemophilia is a major win, but patient uptake could be slow. [ad_2] Source link

New Gene Therapy Could Face Uphill Battle

[ad_1] The potential FDA approval of BioMarin’s gene therapy for hemophilia A would be a major win, but patient uptake could be slow. [ad_2] Source link

Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO

[ad_1] Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workforce executed to align with focus on avexitide;…